All posts

Follow Us

LinkedInInstagramX
Quarterly ResultsArchiveLast updated 12 November 20263 min read

Pharmaids Pharmaceuticals (PHARMAID) Q2 FY27 Swings Back to Loss as Revenue Halves

Pharmaids posted a ₹1.81 crore net loss in Q2 FY27, reversing a profitable Q1 that was propped up by a one-off gain, while revenue fell nearly 50% year-on-year.

By Abhinav Swaroop, CFA, Chief Business Officer: Hexawealth · Created 12 November 2026

Pharmaids Pharmaceuticals' Q2 FY27 saw revenue drop 49.6% year-on-year to ₹4.34 crore. The company swung to a net loss of ₹1.81 crore, erasing the prior quarter's profit which was driven by a ₹4.2 crore exceptional gain.

For a company in the midst of a business transition, quarterly results can be volatile. Pharmaids Pharmaceuticals' September quarter showed just how sharp those swings can be, as a one-off gain that delivered profit in June evaporated.

Revenue for Q2 FY27 was ₹4.34 crore, down 49.6% from the same period last year. The company posted a net loss of ₹1.81 crore, a reversal from the ₹1.87 crore profit reported in Q1. This pushed the trailing-twelve-month net profit margin to -17.4%.

Revenue & profit

Revenue (₹ Cr)

Profit (₹ Cr)

Revenue & profitQ2 FY26 (Sep 2025) 8.61, Q3 FY26 (Dec 2025) 5.43, Q4 FY26 (Mar 2026) 7.18, Q1 FY27 (Jun 2026) 4.12, Q2 FY27 (Sep 2026) 4.34. Q2 FY26 (Sep 2025) -2.53, Q3 FY26 (Dec 2025) -2.65, Q4 FY26 (Mar 2026) -1.08, Q1 FY27 (Jun 2026) 1.87, Q2 FY27 (Sep 2026) -1.81-20-1001020Q2 '26Q3 '26Q4 '26Q1 '27Q2 '27
  • Revenue (₹ Cr), Q2 FY26 (Sep 2025): 8.61
  • Revenue (₹ Cr), Q3 FY26 (Dec 2025): 5.43
  • Revenue (₹ Cr), Q4 FY26 (Mar 2026): 7.18
  • Revenue (₹ Cr), Q1 FY27 (Jun 2026): 4.12
  • Revenue (₹ Cr), Q2 FY27 (Sep 2026): 4.34
  • Profit (₹ Cr), Q2 FY26 (Sep 2025): -2.53
  • Profit (₹ Cr), Q3 FY26 (Dec 2025): -2.65
  • Profit (₹ Cr), Q4 FY26 (Mar 2026): -1.08
  • Profit (₹ Cr), Q1 FY27 (Jun 2026): 1.87
  • Profit (₹ Cr), Q2 FY27 (Sep 2026): -1.81

Revenue (₹ Cr)

Revenue (₹ Cr)Q2 FY26 (Sep 2025) 8.61, Q3 FY26 (Dec 2025) 5.43, Q4 FY26 (Mar 2026) 7.18, Q1 FY27 (Jun 2026) 4.12, Q2 FY27 (Sep 2026) 4.3405101520Q2 '26Q3 '26Q4 '26Q1 '27Q2 '27
  • Revenue (₹ Cr), Q2 FY26 (Sep 2025): 8.61
  • Revenue (₹ Cr), Q3 FY26 (Dec 2025): 5.43
  • Revenue (₹ Cr), Q4 FY26 (Mar 2026): 7.18
  • Revenue (₹ Cr), Q1 FY27 (Jun 2026): 4.12
  • Revenue (₹ Cr), Q2 FY27 (Sep 2026): 4.34

Profit (₹ Cr)

Profit (₹ Cr)Q2 FY26 (Sep 2025) -2.53, Q3 FY26 (Dec 2025) -2.65, Q4 FY26 (Mar 2026) -1.08, Q1 FY27 (Jun 2026) 1.87, Q2 FY27 (Sep 2026) -1.81-4-2024Q2 '26Q3 '26Q4 '26Q1 '27Q2 '27
  • Profit (₹ Cr), Q2 FY26 (Sep 2025): -2.53
  • Profit (₹ Cr), Q3 FY26 (Dec 2025): -2.65
  • Profit (₹ Cr), Q4 FY26 (Mar 2026): -1.08
  • Profit (₹ Cr), Q1 FY27 (Jun 2026): 1.87
  • Profit (₹ Cr), Q2 FY27 (Sep 2026): -1.81
MetricCurrentQ2 FY27 (Sep 2026)PreviousQ1 FY27 (Jun 2026)
Revenue (₹ Cr)
4.34
4.12
Profit (₹ Cr)
-1.81
1.87
PAT Margin (%)
-41.7
45.4

The one-off that flattered Q1

The stark quarter-on-quarter swing is explained by a non-recurring item. According to a MarketsMojo alert, the company's profit in the first half of FY27 was ₹0.06 crore, aided by a ₹4.2 crore exceptional gain in Q1. Without that boost, the underlying business continued to operate at a loss.

Total expenses rose 13.7% sequentially to ₹6.77 crore, even as revenue inched up only 5.3%. Interest costs increased 9.3% to ₹0.66 crore, reflecting the company's debt load.

A balance sheet under strain

The operational challenges are mirrored in the balance sheet. Consolidated borrowings rose to ₹25.50 crore as of September 30, 2026, from ₹22.24 crore at the end of March, as reported by Multibagg.ai. The current ratio stands at 0.77, indicating tight liquidity.

Live Chart

· PHARMAID

(BSE)

ISIN: INE117D01018

Net cash generated from operations was a minimal ₹1.89 lakh for the half-year. With no FII or DII ownership, as noted by StockFin.ai, the company lacks institutional investor support.

The stock showed no immediate reaction, closing at ₹29.17 on the results date. It has declined 34.3% over the past year.

Key Points

  • Pharmaids' Q2 net loss of ₹1.81 crore reversed a profitable Q1 that was driven by a ₹4.2 crore exceptional gain.
  • Consolidated revenue fell nearly 50% year-on-year, though it saw a slight 5.3% sequential increase.
  • The company's borrowings increased to ₹25.50 crore, and it generated negligible operating cash flow of ₹1.89 lakh for H1 FY27.
  • The stock has no institutional ownership and has fallen over 34% in the last twelve months.

Hexa Perspective

The quarter underscores the fragility of Pharmaids' ongoing transition. The core business, excluding one-time gains, is not yet profitable, and revenue remains a fraction of its level from a year ago.

Investors are weighing a business that is burning cash against a debt pile that is still growing. The path to sustainable profitability depends on securing steady contract research and manufacturing service (CRAMS) revenue, for which there is little visibility in these consolidated numbers. Until that revenue base is established, volatility between quarters is likely to remain the norm.

Share or follow HexaWealth

Also read

Want this applied to your portfolio?

Talk to a HexaWealth advisor, or sync your mutual fund data for insights tailored to your holdings.

Pharmaids Pharmaceuticals (PHARMAID) Q2 FY27 results, revenue and profits.

Frequently asked questions

What were Pharmaids Pharmaceuticals' Q2 FY27 results?
Pharmaids Pharmaceuticals reported a Q2 FY27 net loss of ₹1.81 crore on revenue of ₹4.34 crore for the quarter ended September 2026. Revenue declined 49.6% compared to the same quarter last year, while the net loss was an improvement from the ₹2.53 crore loss in Q2 FY26.
Why did Pharmaids Pharmaceuticals' profit swing to a loss in Q2 FY27?
Pharmaids swung to a ₹1.81 crore loss in Q2 FY27 from a ₹1.87 crore profit in Q1 because the prior quarter's profit was not from operations. A MarketsMojo report states the Q1 profit was aided by a ₹4.2 crore exceptional gain, which did not repeat in the September quarter.
What was Pharmaids Pharmaceuticals' revenue in Q2 FY27?
Pharmaids Pharmaceuticals' consolidated revenue for Q2 FY27 (September 2026 quarter) was ₹4.34 crore. This represents a 49.6% decline from the ₹8.61 crore reported in Q2 FY26, but a slight 5.3% increase from the ₹4.12 crore in Q1 FY27.
What was the exceptional gain in Pharmaids Pharmaceuticals' Q1 FY27?
According to a MarketsMojo report, Pharmaids Pharmaceuticals' Q1 FY27 profit was helped by a ₹4.2 crore exceptional gain. This one-off item was the primary driver behind the reported profit of ₹1.87 crore for that quarter, masking the underlying operational performance.
What is Pharmaids Pharmaceuticals' net profit margin for Q2 FY27?
Pharmaids Pharmaceuticals' net profit margin (PAT margin) for Q2 FY27 was -41.7%. This means the company lost ₹41.7 for every ₹100 of revenue it generated during the September 2026 quarter.
How much debt does Pharmaids Pharmaceuticals have?
As of September 30, 2026, Pharmaids Pharmaceuticals had consolidated borrowings of ₹25.50 crore, according to a report by Multibagg.ai. This increased from ₹22.24 crore at the end of March 2026. The debt-to-equity ratio was 0.49.
Did Pharmaids Pharmaceuticals generate positive cash flow in Q2 FY27?
Pharmaids generated minimal cash from operations. For the half-year ended September 2026, net cash from operating activities was just ₹1.89 lakh, as per a Multibagg.ai report. The company ended the period with cash and equivalents of ₹15.70 lakh.
What is the outlook for Pharmaids Pharmaceuticals after Q2 FY27 results?
The outlook remains challenging as the company's core operations are not yet profitable. The Q1 profit was due to a one-off gain. Future performance depends on the company's ability to secure and execute on its contract research and manufacturing (CRAMS) business to generate sustainable revenue and cash flow.
Pharmaids Pharmaceuticals Q2 profit drop
Pharmaids Pharmaceuticals' profit dropped to a loss of ₹1.81 crore in Q2 FY27 from a profit of ₹1.87 crore in Q1 FY27. This swing occurred because the Q1 profit was largely due to a ₹4.2 crore exceptional gain that did not repeat in the September quarter.
Pharmaids Pharmaceuticals Q2 net profit
Pharmaids Pharmaceuticals reported a consolidated net loss of ₹1.81 crore for Q2 FY27 (the September 2026 quarter). This compares to a net loss of ₹2.53 crore in Q2 FY26, representing a year-on-year improvement, but a sharp decline from the ₹1.87 crore profit in Q1 FY27.